Be6A Lung-02Sigvotatug Vedotin and Pembrolizumab for PD-L1 High Non-Small Cell Lung Cancer

This study is about finding out how well a new combination of treatments works for people with a specific type of lung cancer called non-small cell lung cancer (NSCLC). The focus is on patients whose cancer cells show high levels of a protein called PD-L1, which is known to help cancer hide from the immune system. The study aims to see if adding a drug called Sigvotatug Vedotin to an existing treatment, pembrolizumab, is more effective than using pembrolizumab alone. This research is important because it could lead to better treatment options for patients with advanced lung cancer, where current treatments might not be fully effective. Participants in this study will visit the clinic to receive pembrolizumab every six weeks through an IV, which means the medicine is given directly into their veins. Half of the participants will also receive Sigvotatug Vedotin every two weeks in addition to pembrolizumab. The study will monitor how each participant responds to the treatment during regular check-ups. Pembrolizumab can be given for up to two years, while Sigvotatug Vedotin continues as long as it's effective against the cancer. The goal is to see if this new treatment combination can offer improved results for patients with this challenging condition.